{"version":"1.0","type":"link","title":"Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.","author_name":"Safyan RA 외","author_url":"https://prs-insight.online/author/Safyan%20RA","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/149265","thumbnail_width":1200,"thumbnail_height":630}